During the past decade, SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm. conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 1 clinical trials were completed, i.e. on average, 11.1% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm." #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Foundation Medicine, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm." are "Multiple Myeloma" (2 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials), "Cancer" (1 trials), "Cancer of Unknown Primary Site" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm." in a lesser frequency.

Most popular intervention types in "SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm." are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (4 trials), "Alectinib" (2 trials), "Bevacizumab" (2 trials), "Bortezomib" (2 trials) and "Cobimetinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm." are 9 trials for "All" genders.

Currently, there are NaN active trials in "SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm., 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".